Bristol Myers Squibb reported $13.1B in revenue (+6.9% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 11 open management expectations for this company. 1 insider sale recorded. Its latest periodic filing added 62 new risk factors.
The U.S. War Department's Office of Strategic Capital provided a loan to develop domestic production capacity for battery materials. Several public companies describe in their reports how investments in manufacturing and the availability of critical minerals affect their operations.
Bristol Myers Squibb generated $13.1 billion in total net revenue for the third quarter of 2026, compared to $12.2 billion for the same period in 2025. In addition to its financial results, the company reported regulatory approvals and positive interim clinical trial results from its pipeline.
BRISTOL MYERS SQUIBB CO: 12 recorded developments from 1 official source in 2026-10.
2026-10-29: Revenue (us-gaap:Revenues), quarter 2026-07-01 to 2026-09-30: 13,069,000,000 USD (13.1 billion; 13,069 million); same period a year earlier (2025-07-01 to 2025-09-30): 12,222,000,000 USD (12.2 billion; 12,222 million); change +6.9%Source
2026-10-29: Revenue (us-gaap:Revenues), year to date 2026-01-01 to 2026-09-30: 37,532,000,000 USD (37.5 billion; 37,532 million); same period a year earlier (2025-01-01 to 2025-09-30): 35,692,000,000 USD (35.7 billion; 35,692 million); change +5.2%Source
2026-10-29: Net income (us-gaap:NetIncomeLoss), quarter 2026-07-01 to 2026-09-30: 2,162,000,000 USD (2.2 billion; 2,162 million); same period a year earlier (2025-07-01 to 2025-09-30): 2,201,000,000 USD (2.2 billion; 2,201 million); change -1.8%Source
2026-10-29: Net income (us-gaap:NetIncomeLoss), year to date 2026-01-01 to 2026-09-30: 8,156,000,000 USD (8.2 billion; 8,156 million); same period a year earlier (2025-01-01 to 2025-09-30): 5,967,000,000 USD (6 billion; 5,967 million); change +36.7%Source
2026-10-29: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), quarter 2026-07-01 to 2026-09-30: 2,365,000,000 USD (2.4 billion; 2,365 million); same period a year earlier (2025-07-01 to 2025-09-30): 2,528,000,000 USD (2.5 billion; 2,528 million); change -6.4%Source
2026-10-29: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), year to date 2026-01-01 to 2026-09-30: 7,973,000,000 USD (8 billion; 7,973 million); same period a year earlier (2025-01-01 to 2025-09-30): 7,365,000,000 USD (7.4 billion; 7,365 million); change +8.3%Source
2026-10-29: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), year to date 2026-01-01 to 2026-09-30: 8,678,000,000 USD (8.7 billion; 8,678 million); same period a year earlier (2025-01-01 to 2025-09-30): 12,182,000,000 USD (12.2 billion; 12,182 million); change -28.8%Source
2026-10-29: Capital expenditure (us-gaap:PaymentsToAcquirePropertyPlantAndEquipment), year to date 2026-01-01 to 2026-09-30: 996,000,000 USD (996 million); same period a year earlier (2025-01-01 to 2025-09-30): 941,000,000 USD (941 million); change +5.8%Source
2026-10-29: Cash and cash equivalents (us-gaap:CashAndCashEquivalentsAtCarryingValue), as of 2026-09-30: 9,574,000,000 USD (9.6 billion; 9,574 million); previous balance (2025-12-31): 10,209,000,000 USD (10.2 billion; 10,209 million); change -6.2%Source
2026-10-29: Total liabilities (us-gaap:Liabilities), as of 2026-09-30: 65,368,000,000 USD (65.4 billion; 65,368 million); previous balance (2025-12-31): 71,533,000,000 USD (71.5 billion; 71,533 million); change -8.6%Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Key figures
From the 10-Q for the period ended September 30, 2026, filed October 29, 2026. SEC
Latest
Earlier
Change
Revenue quarter
$13.1B
$12.2B
+6.9%
Net income quarter
$2.2B
$2.2B
-1.8%
Diluted EPS quarter
$1.05
$1.08
-2.8%
Dividends per share quarter
$0.63
$0.62
+1.6%
Operating cash flow year to date
$8.7B
$12.2B
-28.8%
Cash and cash equivalents balance
$9.6B
$10.2B
-6.2%
Long-term debt balance
$41.8B
$42.9B
-2.3%
Next results expected around January 28, 2027 (estimate: the quarter ending about December 30, 2026 plus the 29 days the last report took). The company announces the actual date.
As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV
Revenue by quarter, $B
Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
The company plans to develop a new manufacturing campus at Generation Park in Houston, Texas, with a $2.3 billion investment and creation of nearly 500 jobs.
RayzeBio, Inc. plans to invest more than $173 million to expand its radiopharmaceutical manufacturing operations by establishing a new facility in Whitestown, Indiana, with construction expected to begin this year.
The company updated its non-GAAP EPS guidance range to $6.35 to $6.55, inclusive of a $(0.60) per share net impact from Acquired IPRD charges and licensing income.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Changes in risk factors
The 10-Q filed October 29, 2026 compared with the 10-Q filed July 30, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC
Added (62)
The FDA expanded approval of Camzyos for the treatment of symptomatic oHCM to improve functional capacity and symptoms in adults and pediatric patients weighing 30 kg (66 lbs) or more.
FDA approval of Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the treatment of adult patients with MM who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
| Three Months Ended September 30, | | Nine Months Ended September 30,
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.